ROGZ logo

Roche Holding BATS-CHIXE:ROGZ Stock Report

Last Price

CHF 286.15

Market Cap

CHF 229.3b

7D

4.1%

1Y

21.9%

Updated

02 Feb, 2025

Data

Company Financials +

Roche Holding AG

BATS-CHIXE:ROGZ Stock Report

Market Cap: CHF 229.3b

ROGZ Stock Overview

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. More details

ROGZ fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance1/6
Financial Health4/6
Dividends4/6

My Notes

Capture your thoughts, links and company narrative

Roche Holding AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Roche Holding
Historical stock prices
Current Share PriceCHF 286.15
52 Week HighCHF 289.60
52 Week LowCHF 213.00
Beta0.14
1 Month Change11.91%
3 Month Change5.09%
1 Year Change21.95%
3 Year Change-17.29%
5 Year Changen/a
Change since IPO72.38%

Recent News & Updates

Recent updates

Shareholder Returns

ROGZGB PharmaceuticalsGB Market
7D4.1%2.9%2.0%
1Y21.9%3.5%10.8%

Return vs Industry: ROGZ exceeded the UK Pharmaceuticals industry which returned 3.5% over the past year.

Return vs Market: ROGZ exceeded the UK Market which returned 10.8% over the past year.

Price Volatility

Is ROGZ's price volatile compared to industry and market?
ROGZ volatility
ROGZ Average Weekly Movement2.6%
Pharmaceuticals Industry Average Movement7.1%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.7%

Stable Share Price: ROGZ has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: ROGZ's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1896103,249Thomas Schineckerwww.roche.com

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas.

Roche Holding AG Fundamentals Summary

How do Roche Holding's earnings and revenue compare to its market cap?
ROGZ fundamental statistics
Market capCHF 229.34b
Earnings (TTM)CHF 8.28b
Revenue (TTM)CHF 62.40b

27.5x

P/E Ratio

3.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ROGZ income statement (TTM)
RevenueCHF 62.40b
Cost of RevenueCHF 15.73b
Gross ProfitCHF 46.66b
Other ExpensesCHF 38.39b
EarningsCHF 8.28b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Jul 24, 2025

Earnings per share (EPS)10.41
Gross Margin74.79%
Net Profit Margin13.27%
Debt/Equity Ratio95.9%

How did ROGZ perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

93%

Payout Ratio

Does ROGZ pay a reliable dividends?

See ROGZ dividend history and benchmarks
When do you need to buy ROGZ by to receive an upcoming dividend?
Roche Holding dividend dates
Ex Dividend DateMar 27 2025
Dividend Pay DateMar 31 2025
Days until Ex dividend53 days
Days until Dividend pay date57 days

Does ROGZ pay a reliable dividends?

See ROGZ dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 05:08
End of Day Share Price 2025/01/31 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Roche Holding AG is covered by 56 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
John StaszakArgus Research Company
Gerhard SchwarzBaader Helvea Equity Research